Original analysis on competitive landscapes, regulatory decisions, deal activity, and catalyst events in biotech.
A comprehensive primer on the molecule poised to reshape obesity therapeutics — from Chugai's polycyclic scaffold to Lilly's NDA submission, the competitive landscape, and the regulatory catalysts ahead in 2026.
Read full analysis →Interactive tracker of 38+ in vivo CAR-T programs across viral and non-viral delivery. $7.5B+ in M&A, clinical data from 6 programs, and catalysts through 2027.
CBER Director Vinay Prasad overruled career FDA reviewers to reject Moderna’s mRNA flu vaccine application. Sector-wide implications for mRNA platform valuation and CBER regulatory risk across vaccines, gene therapies, and cell therapies.
New analysis published weekly. Get alerts for new insights.
Subscribe to Insights